MD News and Information

Scleroderma related interstitial lung disease can be treated with new promising treatment

Author:
Date Published: January-2016
Source: Bel Marra Health

Scleroderma related interstitial lung disease can be treated with new promising treatment. Interstitial lung disease is common in systemic sclerosis and is the leading cause of death. If discovered early on, though, prognosis is positive for patients. Interstitial lung disease is a term to describe a large group of disorders which refers to the scarring of lung tissue and supporting of the air sacs. This scarring can contribute to lung stiffness which affects a person’s ability to breathe which limits oxygen from entering the bloodstream.

 

Colonic Microbial Signatures in Systemic Sclerosis How do they affect clinical manifestations?

Author:
Date Published: January-2016
Source: Rheumatology News

Compared with healthy controls, patients with systemic sclerosis (SSc) harbor a distinct colonic microbial signature that may perpetuate immunological aberrations and contribute to clinical manifestations of SSc. This according to a study of 17 patients with SSc and 17 age- and sex-matched healthy controls. Researchers found:

 

Anti-IFI16 Antibodies in Scleroderma - Studying associations with digital gangrene

Author:
Date Published: January-2016
Source: Rheumatology News

Anti-interferon inducible protein 16 (Anti-IFI16) antibodies are associated with digital gangrene in scleroderma. This according to a study of sera from 94 patients with scleroderma and 47 healthy controls and a separate case-control study of 39 patients with scleroderma and digital gangrene and 39 patients with scleroderma and Raynaud’s alone. Researchers found:

 

Telling Jewels From Junk in DNA

Author: Carl Zimmer
Date Published: January-2016
Source: New York Times

When you learned about genes in high school, chances are it went something like this: Our DNA holds about 20,000 protein-coding genes. To make a protein, a cell makes a copy of the corresponding gene, in the form of a single-stranded molecule called RNA. The cell uses the RNA molecule as a template to make the protein. And then the protein floats off to do its job. That’s certainly true. But there’s more to the story.

 

Experimental Compound Shows Promise in Reversing Skin Disease Associated with Systemic Sclerosis

Author: Collee Labbe
Date Published: January-2016
Source: NIAMS Spotlight on Research

A new drug appears to alter the expression of certain genes associated with systemic sclerosis by blocking a key protein, and also leads to clinical improvements in the skin, according to a study funded in part by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The study was published in the Journal of Clinical Investigation. Systemic sclerosis, a severe form of scleroderma, is a chronic connective tissue disease that affects multiple organs and tissues in the body. It can lead to fibrosis, or hardening, of the skin and other organs such as the lungs, kidneys and heart. Currently, no effective treatments exist. Because the disease affects everyone differently, finding therapies has been challenging.

 

Idiopathic Pulmonary Fibrosis Drugs Makes Inroads in Systemic Sclerosis Market

Author:
Date Published: January-2016
Source: Clinical Trials Arena

Pharmaceutical giant, Boehringer Ingelheim (BI), is poised to begin a Phase III trial of its idiopathic pulmonary fibrosis (IPF) drug, Ofev (nintedanib) as a treatment for systemic sclerosis-related interstitial lung disease (SSc-ILD). Ofev initially gained approval by the Food and Drug Administration (FDA) in October 2014 and by the European Medicines Agency (EMA) in January 2015. Roche and Genentech's Esbriet, arguably BI's closest competitor in the field, is more widely known than Ofev. Despite being available in Europe since 2011, Esbriet gained FDA approval on the same day as Ofev.

 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 11 of 21